Cidara Therapeutics to Present Ongoing Development of
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...
Source: globenewswire.com
📰 Veronica Eames News
Page 3 - Veronica Eames News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Veronica Eames. Real-time updates on events, politics, business and more.
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
SAN DIEGO, June 20, 2023 -- Cidara Therapeutics, Inc. , a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious... | June 20, 2023
Source: marketscreener.com
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
SOUTH SAN FRANCISCO, Calif., June 07, 2023 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver... | June 7, 2023
Source: marketscreener.com
Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator
Innosuisse supports 53 companies out of 752 applications with total CHF 112MAraris’ awarded grant will be used to support further development and...
Philipp Spycher Veronica Eames Lifesci Communications Paul Scherrer Institute Swiss Accelerator Innosuisse Swiss Accelerator
Source: globenewswire.com
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™
– U.S. launch of REZZAYO by Melinta expected in mid-2023 –– Company eligible to receive up to an additional $47 million in milestones from multiple existing partnerships based on... | April 24, 2023
Source: marketscreener.com
Araris Biotech AG Announces Strategic Investment with
Samsung Ventures makes investment in ArarisProceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC)...
Philipp Spycher Veronica Eames Samsung Biologics Samsung Venture Investment Corporation Ventures Lifesci Communications Samsung Life Science Fund
Source: globenewswire.com
Cidara Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, March 31, 2023 -- Cidara Therapeutics, Inc. , a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases,... | March 31, 2023
Source: marketscreener.com
Araris Biotech AG to Present Preclinical Data at American
ZURICH, Switzerland, March 14, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker...
United States Orange County Convention Center Philipp Spycher Veronica Eames Paul Scherrer Institute American Association For Cancer Research
Source: globenewswire.com
Providence Therapeutics Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer
Providence Therapeutics Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer - read this article along with other careers information, tips and advice on BioSpace
Brad Sorenson Noy Wong Veronica Eames Excellence At Abbvie Inc Immunology For The Genomics Resource Center Illinois Institute Of Technology
Source: biospace.com
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependenceStudy design allows for the assessment of the
United States Al Medwar John Temperato Patrickh Griffin Veronica Eames National Institute Of Diabetes
Source: finanznachrichten.de